A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).
Massimo Cristofanilli
No relevant relationships to disclose
Stephen R. D. Johnston
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Alexey Manikhas
Research Funding - GlaxoSmithKline
Henry Leonidas Gomez
No relevant relationships to disclose
Oleg Gladkov
Research Funding - GlaxoSmithKline
Zhimin Shao
No relevant relationships to disclose
Sufia Safina
Research Funding - GlaxoSmithKline
Stephen D. Rubin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sulabha Ranganathan
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Suman Lata
Employment or Leadership Position - GlaxoSmithKline
Maureen E. Trudeau
Honoraria - GlaxoSmithKline